Youness Lagoubi1, Mohamed Tahar Sfar2, Jorge A Gomez3. 1. GSK, Casablanca, Morocco. 2. Department of Paediatrics, Tahar Sfar University Hospital, Mahdia, Tunisia. 3. GSK, Buenos Aires, Argentina.
Abstract
BACKGROUND: In response to the substantial clinical and economic burden of diseases caused by Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) in Tunisia, the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) was recently introduced into the national immunization program. However, there has yet to be a full-scale health economic analysis comparing currently available pneumococcal conjugate vaccines (PCVs) in Tunisia. METHODS: A Markov model that simulated the disease processes of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) over a newborn cohort lifetime was used to evaluate the cost-effectiveness/utility of PHiD-CV and the 13-valent pneumococcal conjugate vaccine (PCV13) from payer's perspective, using 3% discounting. Vaccine effects were considered for up to 9 years of age. RESULTS: Vaccination with PHiD-CV or PCV13 was estimated to avert approximately 700 cases of IPD (200 meningitis, 500 bacteremia), and around 5,000 cases of all-cause pneumonia. However, PHiD-CV vaccination was estimated to avert around 4,000 additional AOM cases (18,000) versus PCV13 (14,000). Both PCVs were demonstrated to be cost-effective interventions, but PHiD-CV was estimated to generate additional cost savings of almost $1 million US dollars (USD) with similar levels of clinical benefits. An additional scenario which incorporated serotype-specific vaccine efficacy found no significant change in overall results. CONCLUSION: PCVs are a cost-effective strategy to relieve the burden associated with diseases caused by S. pneumoniae and NTHi in Tunisia. PHiD-CV is more cost-effective than PCV13, generating similar health benefits, at a reduced net cost of almost $1 million USD per vaccinated cohort.
BACKGROUND: In response to the substantial clinical and economic burden of diseases caused by Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) in Tunisia, the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) was recently introduced into the national immunization program. However, there has yet to be a full-scale health economic analysis comparing currently available pneumococcal conjugate vaccines (PCVs) in Tunisia. METHODS: A Markov model that simulated the disease processes of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media (AOM) over a newborn cohort lifetime was used to evaluate the cost-effectiveness/utility of PHiD-CV and the 13-valent pneumococcal conjugate vaccine (PCV13) from payer's perspective, using 3% discounting. Vaccine effects were considered for up to 9 years of age. RESULTS: Vaccination with PHiD-CV or PCV13 was estimated to avert approximately 700 cases of IPD (200 meningitis, 500 bacteremia), and around 5,000 cases of all-cause pneumonia. However, PHiD-CV vaccination was estimated to avert around 4,000 additional AOM cases (18,000) versus PCV13 (14,000). Both PCVs were demonstrated to be cost-effective interventions, but PHiD-CV was estimated to generate additional cost savings of almost $1 million US dollars (USD) with similar levels of clinical benefits. An additional scenario which incorporated serotype-specific vaccine efficacy found no significant change in overall results. CONCLUSION: PCVs are a cost-effective strategy to relieve the burden associated with diseases caused by S. pneumoniae and NTHi in Tunisia. PHiD-CV is more cost-effective than PCV13, generating similar health benefits, at a reduced net cost of almost $1 million USD per vaccinated cohort.
Authors: Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Corinne Holtzman; Lee H Harrison; Shelley M Zansky; Jennifer B Rosen; Arthur Reingold; Karen Scherzinger; Ann Thomas; Ramon E Guevara; Tasneem Motala; Jeffrey Eason; Meghan Barnes; Susan Petit; Monica M Farley; Lesley McGee; James H Jorgensen; Cynthia G Whitney Journal: Lancet Respir Med Date: 2016-03-14 Impact factor: 30.700
Authors: Nick J Andrews; Pauline A Waight; Polly Burbidge; Emma Pearce; Lucy Roalfe; Marta Zancolli; Mary Slack; Shamez N Ladhani; Elizabeth Miller; David Goldblatt Journal: Lancet Infect Dis Date: 2014-07-17 Impact factor: 25.071
Authors: Jorge Alberto Gomez; Juan Carlos Tirado; Aldo Amador Navarro Rojas; Maria Mercedes Castrejon Alba; Oleksandr Topachevskyi Journal: BMC Public Health Date: 2013-10-30 Impact factor: 3.295
Authors: Carla Magda Allan S Domingues; Jennifer R Verani; Ernesto Issac Montenegro Renoiner; Maria Cristina de Cunto Brandileone; Brendan Flannery; Lucia Helena de Oliveira; João Barberino Santos; José Cássio de Moraes Journal: Lancet Respir Med Date: 2014-04-10 Impact factor: 30.700
Authors: Lucia Helena de Oliveira; Luiz Antonio B Camacho; Evandro S F Coutinho; Martha S Martinez-Silveira; Ana Flavia Carvalho; Cuauhtemoc Ruiz-Matus; Cristiana M Toscano Journal: PLoS One Date: 2016-12-12 Impact factor: 3.240